Trials / Completed
CompletedNCT02343718
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
A Study of Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 1 Year – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
Detailed description
Vinblastine is already approved in the treatment of some types of cancer in children and temsirolimus is already used to treat some adult cancers in Canada. Temsirolimus has been shown to slow the growth of tumours in animals but it is not known if it can also slow tumour growth in children. Laboratory studies suggest that giving both vinblastine and temsirolimus may offer better results than giving vinblastine alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinblastine | |
| DRUG | Temsirolimus |
Timeline
- Start date
- 2015-06-24
- Primary completion
- 2017-09-28
- Completion
- 2019-01-16
- First posted
- 2015-01-22
- Last updated
- 2023-08-04
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02343718. Inclusion in this directory is not an endorsement.